PRAME, WT1 and XIAP tumor-associated genes expression in multiple myeloma patients
https://doi.org/10.17650/1818-8346-2009-0-2-52-57
Abstract
Tumor-associated genes (PRAME, WT1 and XIAP) expression study is conducted in 34 patients with multiple myeloma (MM) in disease onset and after chemotherapy (VAD, 20 pts) and proteosom inhibitor therapy (10 pts). PRAME, WT1 и XIAP gene expression in bone marrow cells detected by polymerase chain reaction (PCR) method. PRAME gene expression in 62% primary patients was revealed, thus expression median was 0.3% that almost in 100 times greater than in bone marrow donors (0.0035%). WT1 gene expression in 20% patients was detected, and it was determined only in PRAMEpositive patients. At diagnosis XIAP gene expression was revealed in all MM patients, thus expression median was more 10 times greater than in the control groups (28% versus 2%). In patients with PRAME hyperexpression partial response was achieved only in 25% of cases, while in patients with low or absence of PRAME expression VAD therapy was effective in 75% of cases (р=0,06). After bortezomib treatment XIAP gene expression level was significantly decreased with complete and partial remission achievement: from 11-325% (median – 66%) to 1-123% (median – 20%). In cases of tumor resistance to bortezomib treatment XIAP expression increased from 16-127% (median – 36%) to 22-528% (median – 121%).
About the Authors
T. V. Gaponova
Hematological Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
L. P. Mendeleeva
Hematological Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
A. V. Misurin
Hematological Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
E. V. Varlamova
Hematological Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
V. G. Savchenko
Hematological Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
References
1. Kumar S.K., Rajkumar S.V., Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516–20.
2. Менделеева Л.П., Покровская О.С. Протокол высокодозной химиотерапии и трансплантации аутологичных стволовых гемопоэтических клеток при множественной миеломе. В кн.: Программное лечение лейкозов. Под ред. В.Г. Савченко. М., 2008. с. 343–58.
3. Burington B., Barlogie B., Zhan F. et al. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in Multipal Myeloma. Clin Cancer Res 2008;14(15):4821–9.
4. Leilst M., Jддttelд M. Four deaths and funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589–98.
5. Andrade V.C., Vettore A.L., Felix R.S. et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008;8:2–10.
6. Matsushita M., Yamazaki R., Ikeda H. et al. Preferentally expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic metods for hematological malignacies. Leukem Lymph 2003;44(3):439–44.
7. Epping M.T., Bernards R. A causal role for the human tumor antigen prreferntially expressed antigen of melanoma in cancer. Cancer Res 2006;66(22):10639–42.
8. Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A. et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphoid leukemia and mantle cell lymphoma. Leukem Res 2006;30:1333–9.
9. Абраменко И.В., Белоус Н.И., Крячок И.А., Мисюрин А.В. Экспрессия гена PRAME при миеломной болезни. Тер арх 2004;(7):35–40.
10. Yang L., Han Y., Saiz F.S. et al. A tumor suppressor and oncogene: the WT1 story. Leucemia 2007;21:868–76.
11. Gaiger A., Reese V., Disis M.L. et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96(4):1480–9.
12. Holclic M., Korneluk R.G. X-chromosome-linked Inhibitor of Apoptosis (XIAP). Nat Rev Mol Cell Biol 2001;2:550–6.
13. Sun Y.E. 3 Ubiquitine ligases as cancer targets and biomarkers. Neoplasia 2006;8:645–54.
14. Silke J., Ekert P.G., Day C.L. et al. Direct inhibitor of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. The EMBO J 2001;20(12):3114–23.
15. Chomcrynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 1987;162:156–9.
Review
For citations:
Gaponova T.V., Mendeleeva L.P., Misurin A.V., Varlamova E.V., Savchenko V.G. PRAME, WT1 and XIAP tumor-associated genes expression in multiple myeloma patients. Oncohematology. 2009;(2):52-57. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-2-52-57
Views:
285
Email this article 